New York, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "FLT3 Inhibitors Market - A Global and Country Analysis: Focus on Commercialized Therapy, Potential ...
Pooled evidence from 2 randomized trials and 6 observational cohorts suggests posttransplant gilteritinib maintenance may ...
Dublin, Sept. 08, 2022 (GLOBE NEWSWIRE) -- The "FLT3 Inhibitors Market - A Global and Country Analysis: Focus on Commercialized Therapy, Potential Pipeline Product, and Region - Analysis and Forecast, ...
Patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) had a high response rate and prolonged event-free survival (EFS) following treatment with an investigational FLT3 inhibitor and ...
ATLANTA -- Adding a targeted drug to intensive chemotherapy significantly improved outcomes in FLT3-mutated acute myeloid leukemia (AML) versus historical controls treated with induction chemotherapy ...
AML induction shifts beyond 7+3 as venetoclax, hypomethylating agents, and FLT3 inhibitors drive less toxic combos and oral ...
The fms-like tyrosine kinase 3 (FLT3) plays an important role in both normal and malignant hematopoiesis. Activating mutations in the FLT3 receptor can be detected in approximately 30% of acute ...
Hypocellular acute myeloid leukemia: Better or worse prognosis. Background: FLT3 (fms-related tyrosine kinase 3) with internal tandem duplication (ITD) is a known adverse prognostic factor in normal ...
Through a groundbreaking new gene sequencing technology, researchers have demonstrated that the gene FLT3 is a valid therapeutic target in Acute Myeloid Leukemia, AML, one of the most common types of ...
Credit: Daiichi Sankyo. Vanflyta is expected to be available in the coming weeks. The Food and Drug Administration (FDA) has approved Vanflyta ® (quizartinib) in combination with standard cytarabine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results